Clinical Trial Update: Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation [Phase 2]

View source ↗

Summary

Phase 2 study investigating Pyrotinib in previously treated non-small cell lung cancer with EGFR or ERBB2 exon 20 insertion mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN